Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ: SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the company’s full-year revenue guidance of $695 million at the midpoint came in 1.1% below analysts’ estimates. Its GAAP loss of $0.80 per share was 13.7% above analysts’ consensus estimates.

Is now the time to buy SUPN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward guidance. Management attributed quarterly growth to robust demand for Qelbree and GOCOVRI, as well as initial contributions from Onapgo and collaboration revenue from Zurzuvae. CEO Jack Khattar acknowledged that supply constraints for Onapgo limited the company’s ability to fully meet patient demand, describing the issue as a “high-quality problem” but one that requires urgent resolution. Management also cited higher operating expenses related to the Sage acquisition as a key factor weighing on profitability.

Looking forward, Supernus’ updated full-year guidance reflects expectations for continued momentum from its four key growth products, though supply issues with Onapgo and integration expenses from recent acquisitions may impact near-term results. CEO Jack Khattar signaled that resolving Onapgo’s capacity bottleneck is a top priority, noting, “We’re working around the clock literally with our suppliers trying to line up more batches, line up more deliveries.” The company’s outlook also depends on successful integration of the Sage business, continued expansion in women’s health, and advancing its pipeline programs in central nervous system disorders.

Key Insights from Management’s Remarks

Management identified strong sales of Qelbree, GOCOVRI, and Zurzuvae as key drivers, while Onapgo’s early success was tempered by supply limitations and one-off acquisition costs.

• Qelbree growth sustained: Qelbree delivered 23% prescription growth and 31% net sales growth year-over-year, supported by strength in both pediatric and adult ADHD segments.
• Onapgo launch constrained by supply: Onapgo’s initial demand outpaced supply, with cartridge filling limitations slowing new patient starts. Management is prioritizing inventory for existing patients while seeking to resolve the bottleneck.
• Zurzuvae collaboration revenue boost: The integration of Sage and the addition of Zurzuvae contributed meaningfully to collaboration revenues. Management expects up to $200 million in annual synergies by mid-2026.
• GOCOVRI momentum continues: GOCOVRI posted 15% net sales growth, attributed to increasing prescriptions and a broader prescriber base in movement disorders.
• Acquisition costs weigh on margins: The quarter’s operating margin was significantly impacted by $70 million in Sage-related acquisition costs and higher intangible asset amortization, leading to a GAAP operating loss despite underlying product growth.

Drivers of Future Performance

Management’s outlook centers on resolving Onapgo supply constraints, maximizing growth from core products, and disciplined expense control amid ongoing integration activities.

• Onapgo supply resolution critical: Restoring full availability of Onapgo is seen as essential for sustaining momentum and recapturing patients who may have turned to alternatives during the supply shortage. Management emphasized that capacity improvements are underway, but timing remains uncertain.
• Pipeline and market expansion: Supernus is advancing new development programs, including planned trials for SPN-443 in ADHD and SPN-820 in major depressive disorder. The company also aims to leverage its infrastructure to pursue deals in women’s health and rare CNS disorders.
• Expense discipline post-acquisition: With integration of Sage nearing completion, management expects non-GAAP operating earnings to improve as one-time acquisition costs subside. However, ongoing R&D and SG&A investments are likely to keep reported margins under pressure in the near term.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will closely monitor (1) progress in resolving Onapgo’s supply chain bottleneck and its impact on patient retention, (2) the pace of integration and realized synergies from the Sage acquisition, and (3) continued prescription growth for Qelbree and GOCOVRI. Advancements in pipeline programs and potential business development activity in women’s health or rare CNS disorders will also be important milestones.

Supernus Pharmaceuticals currently trades at $50.01, down from $57.08 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.